The premarket assessment of the cost-effectiveness of a predictive technology “Straticyte™” for the early detection of oral cancer: a decision analytic model

Abstract Introduction Approximately half of oral cancers are detected in advanced stages. The current gold standard is histopathological assessment of biopsied tissue, which is subjective and dependent on expertise. Straticyte™, a novel prognostic tool at the pre-market stage, that more accurately i...

Full description

Bibliographic Details
Main Authors: S. Khoudigian-Sinani, G. Blackhouse, M. Levine, L. Thabane, D. O’Reilly
Format: Article
Published: BMC 2017-10-01
Series:Health Economics Review
Online Access: